Prof. Knop describes the possible mechanisms of CV/CKD risk reduction by GLP-1 receptor activation.
Frederik Persson shows evidence of renoprotective effects with GLP-1RA treatment, by discussing various small clinical trials as well as CVOTs with GLP-1RAs.
We have entered a new era for treatment of cardiorenal disease in diabetes. Prof. John Deanfield discusses evidence on the need for early management and alteration of upstream factors that affect renal and cardiac function in diabetic patients.
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants
Slides as educational service to PACE members and meeting participants